QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:VERU

Veru - VERU Stock Forecast, Price & News

$5.76
-0.15 (-2.54%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.72
$6.09
50-Day Range
$4.78
$6.41
52-Week Range
$4.34
$24.55
Volume
1.24 million shs
Average Volume
1.77 million shs
Market Capitalization
$464.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.50

Veru MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
481.6% Upside
$33.50 Price Target
Short Interest
Bearish
22.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($1.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

616th out of 1,029 stocks

Pharmaceutical Preparations Industry

306th out of 501 stocks

VERU stock logo

About Veru (NASDAQ:VERU) Stock

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Is There any Hope for Veru Stock?
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript
Veru Full Year 2022 Earnings: Misses Expectations
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
Is Veru a Buy?
Is It Too Late to Buy Veru Stock?
Why Shares of Veru Fell 10.33% on Monday
Why Veru Stock Was Losing One-Third of Its Value This Week
Why Veru Stock Is Cratering Today
UPDATE 3-U.S.FDA panel votes against Veru's COVID-19 pill
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings
12/05/2022
Today
2/03/2023
Next Earnings (Confirmed)
2/09/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.50
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+481.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-83,780,000.00
Net Margins
-212.88%
Pretax Margin
-212.28%

Debt

Sales & Book Value

Annual Sales
$39.35 million
Book Value
$1.01 per share

Miscellaneous

Free Float
61,999,000
Market Cap
$464.37 million
Optionable
Optionable
Beta
-0.25

Key Executives

  • Mitchell Shuster Steiner
    Chairman, President & Chief Executive Officer
  • Michele Greco
    Chief Financial & Administrative Officer
  • Robert H. Getzenberg
    Executive Vice President-Medical Affairs
  • Domingo Rodriguez
    Executive Vice President-Clinical Operations
  • K. Gary Barnette
    Chief Scientific Officer













VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price forecast for 2023?

5 brokers have issued 1-year target prices for Veru's shares. Their VERU share price forecasts range from $18.00 to $55.00. On average, they anticipate the company's stock price to reach $33.50 in the next year. This suggests a possible upside of 479.6% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2023?

Veru's stock was trading at $5.28 on January 1st, 2023. Since then, VERU stock has increased by 9.5% and is now trading at $5.78.
View the best growth stocks for 2023 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our VERU earnings forecast
.

How can I listen to Veru's earnings call?

Veru will be holding an earnings conference call on Thursday, February 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "9127050".

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) announced its earnings results on Monday, December, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.22. The company earned $2.59 million during the quarter, compared to the consensus estimate of $11.51 million. Veru had a negative net margin of 212.88% and a negative trailing twelve-month return on equity of 69.57%.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by many different retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%), Strs Ohio (0.08%), Kestra Private Wealth Services LLC (0.08%), Mendel Capital Management LLC (0.07%), SG Americas Securities LLC (0.05%) and Private Advisor Group LLC (0.03%). Insiders that own company stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $5.78.

How much money does Veru make?

Veru (NASDAQ:VERU) has a market capitalization of $465.98 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Veru have?

The company employs 252 workers across the globe.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 2/3/2023 by MarketBeat.com Staff